Merck’s Proscar® For Prostate Cancer “Not Recommended”: 17-0, At FDA Panel

Not really surprising — given the tenor of the remarks of the FDA staff, this morning. In any event, here is the detail on Proscar® (finasteride) portion of today’s meeting, from a Bloomberg story on it:

. . . .Outside advisers to the Food and Drug Administration voted 17-0 with one abstention today that Proscar has an unfavorable balance of risks and benefits in healthy men at least 55 years old. Merck, based in Whitehouse Station, New Jersey, asked to add data from its studies in prostate cancer to the prescribing information for Proscar, approved in 1992. . . .

Wow — 17-0, huh? — a complete shutout. So it goes.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s